Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROR1 | Q01973 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439221 | 0.79 | ROR1 (0.36) | ROR1MRGPRX4CYP19A1 | |
| SCHEMBL6434923 | 0.78 | ROR1 (0.36) | ROR1NPY1RSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6437544 | 0.77 | ROR1 (0.33) | ROR1SLC6A4CYP19A1 | |
| SCHEMBL613626 | 0.77 | ROR1 (0.36) | ROR1NPY1RSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6433053 | 0.76 | ROR1 (0.40) | ROR1NPY1RCYP19A1 | |
| SCHEMBL2133033 | 0.75 | DRD2 (0.44) | MRGPRX4SLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL6485919 | 0.73 | FFAR4 (0.41) | — | |
| SCHEMBL6433135 | 0.72 | PDE10A (0.39) | ROR1NPY1RCYP19A1 | |
| SCHEMBL6438560 | 0.71 | ROR1 (0.41) | ROR1CYP19A1 | |
| SCHEMBL615753 | 0.70 | ROR1 (0.37) | ROR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | ROR1 472/4885MRGPRX4 1001/4885NPY1R 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.